Abstract A 10-day-old child was treated for neonatal herpes simplex virus (HSV) central nervous system (CNS) disease with 21 days of intravenous acyclovir and 6 months of oral acyclovir. She presented 7 years later with HSV CNS disease and new lesions in her brain, illustrating the non-benign nature of delayed recurrent HSV CNS disease.
Despite advances in antiviral therapy, neonatal herpes simplex virus (HSV) central nervous system (CNS) disease is associated with significant neurological morbidity. Neurological sequelae are likely secondary to the initial CNS infection, as well as persistent and periodic reactivation of HSV within the CNS that leads to inflammation and further neurological deterioration [1] . Sources of HSV reactivation may include (1) latent virus in trigeminal ganglia with subsequent spread to the brain parenchyma or (2) reactivation of latent virus within the brain parenchyma itself [2] . In either case, to reduce this ongoing inflammation and further neurological morbidity, neonates are currently treated with a 21-day course of intravenous (IV) acyclovir followed by a 6-month course of oral acyclovir.
Clinically recurrent neonatal HSV CNS disease occurs in approximately 8% of neonates after initial antiviral treatment [3] with the onset of recurrence usually occurring within weeks to months of the initial infection [4] . Recurrence during or after prophylactic oral acyclovir treatment is even more rare with only a few documented cases [5, 6] . In this study, we report a pediatric case of delayed recurrent HSV-2 CNS disease in a child who had neonatal HSV-2 CNS disease and who received acyclovir treatment and prophylaxis for 6 months.
CASE REPORT
A 7-year-old previously healthy white female presented with a 3-day history of severe, diffuse headache, and a new onset of photophobia, phonophobia, neck stiffness, dizziness, and vomiting. There was no history of fever, confusion, personality changes, or decreased level of consciousness, and she had not sustained any preceding head trauma. Sick contacts included several children with vomiting and headache at her daycare facility.
Her past medical history was significant for herpes simplex type 2 (HSV-2) neonatal CNS disease diagnosed at 10 days of age. At that time, she presented with fever, lethargy, and decreased oral intake. She had no rashes or signs of skin, eye, or mucous membrane involvement. Cerebrospinal fluid (CSF) analysis demonstrated pleocytosis (1198 × 10 6 /liter) with 84% lymphocytes, 13% monocytes, and 3% basophils, elevated protein concentration (1.51 g/L), and decreased glucose (2.0 mmol/L). There was no bacterial growth from the CSF, and polymerase chain reaction (PCR) analysis of CSF was positive for HSV-2 deoxyribonucleic acid (DNA). Brain magnetic resonance imaging at 13 days of age was normal. Ophthalmological examination at 19 days of age showed no evidence of keratitis and no abnormalities in the anterior or posterior chambers, and brainstem audiometry was within normal limits. She received a total of 21 days of IV acyclovir (60 mg/kg per day), and a repeat lumbar puncture performed upon completion of antiviral therapy was negative for HSV-2 DNA. When therapy was completed, she was enrolled in the Collaborative Antiviral Study Group (CASG) placebo-controlled study of oral acyclovir suppressive therapy (300 mg/m 2 body-surface area per dose orally, 3 times a day for 6 months) [7] where she was randomized to receive active treatment. After receiving 6 months of oral acyclovir suppression in the CASG trial, she had close pediatric follow up and remained asymptomatic and healthy for the next 7 years of life with no neurological or developmental sequelae. She had no subsequent acyclovir treatment until the current illness at 7 years of age.
At the time of this admission, she had a 2-day history of headache, vomiting, and neck stiffness. There was no history of fever, e178 • JPIDS 2017:6 (December) • Henderson et al diarrhea, cough, coryza, or rashes. Physical examination revealed a pale, alert 7-year-old female with a Glasgow coma scale score of 15/15. She had a temperature 36.4°C, pulse of 101 beats per minute, respiratory rate of 46 breaths per minute, and blood pressure 106/71 mmHg (sitting). She had slight nuchal rigidity, a positive Brudzinski's sign, and negative Kernig's sign. There was no evidence of conjunctival injection, papilledema or focal neurological findings, and cranial nerve, sensory, and motor exams were all unremarkable. The remainder of her examination was within normal limits. Head computerized tomography scan was interpreted as normal. Cerebrospinal fluid analysis was significant for pleocytosis (1400 × 10 6 /liter) with 84% lymphocytes, 11% monocytes, and 5% basophils, elevated protein concentration (0.97 g/L), and normal glucose (3.1 mmol/L). Cerebrospinal fluid demonstrated no bacterial growth, and CSF PCRs were negative for enterovirus, parechovirus, HSV-1, and varicella zoster virus, and positive for HSV-2 DNA. Other laboratory results included a negative blood culture and negative stool on direct electron microscopy for rotavirus, adenovirus, and small round structured viruses. A working diagnosis of recurrent HSV-2 meningitis was made.
Brain magnetic resonance imaging (MRI) on day 8 of admission, when compared with neuroimaging done 7 years prior (during her initial infection), now showed multiple peripheral white matter lesions most in keeping with microangiopathic changes ( Figure 1A ). The findings of parenchymal brain involvement suggested recurrent HSV CNS disease as a more appropriate diagnosis. She received 21 days of IV acyclovir, with complete resolution of her symptoms by day 3 of treatment. She remained afebrile throughout the duration of illness.
A follow-up lumbar puncture done on day 18 of therapy still showed some evidence of pleocytosis (white blood cell count of 73 × 10 6 /liter), but PCR was negative for HSV-2. The patient was discharged on 12 months of suppressive oral acyclovir. An MRI 4 months later showed that the majority of the white matter lesions were unchanged, a few lesions had become less conspicuous, and there were no new lesions. The lesions were believed to be nonspecific, but given the history of viral CNS disease, likely postinflammatory ( Figure 1B) . At 1-year follow up she, remained asymptomatic and developmentally normal.
DISCUSSION
Recurrent neonatal HSV CNS disease is rare, with a reported prevalence of 8% [3] . Neonatal HSV-2 CNS disease most commonly recurs during the first year of life [4] . In this case, the HSV-2 CNS infection recurred 7 years after the primary neonatal infection in a child who received 6 months of acyclovir prophylaxis. To our knowledge, there are no cases of such delayed reactivation of HSV-2 in the CNS after neonatal infection reported in the literature.
The CASG study, in which this patient participated, documented improved developmental outcomes with 6 months of antiviral suppressive therapy [4] . This suggests that subclinical reactivation of the virus occurs within the brain after acute treatment of neonatal CNS disease. Suppressive therapy for 2 years does not further improve developmental outcomes, suggesting that most, or all, subclinical damage occurs within the first several months after the acute infection [7] . However, our case documents that such reactivation may occur even years later. This is an important recognition that adds to our knowledge of the scope of natural history of HSV-2 CNS disease after neonatal infection. Furthermore, the white matter changes noted on MRI after this recurrence suggests that recurrent HSV CNS disease is far from a benign entity.
In the adult literature, a "rebound" phenomenon in the first year after discontinuing antiviral prophylaxis has been described. Adults who had been treated for HSV-2 meningitis were randomized to 1 year of placebo or valacyclovir prophylaxis (at a dose of 500 mg twice daily). In the first year, there was no significant difference in recurrence rate, but in the year after discontinuing medication, there was a significantly higher recurrence risk of HSV-2 meningitis in the group who received antiviral prophylaxis versus those who received placebo [8] . This suggests that suppressive therapy of HSV meningitis may delay recurrences, increasing the likelihood of recurrence or rebound once suppression is stopped.
CONCLUSIONS
Pediatric data have shown that acyclovir prophylaxis (at a dose of 300 mg/m 2 per dose three times a day) improves neurodevelopmental outcomes in infants with neonatal HSV involving the CNS [4] , and it remains standard of care for infants to receive prophylactic acyclovir for 6 months after HSV CNS disease. Nevertheless, it remains possible that later-onset CNS Figure 1 . (A) Magnetic resonance imaging of the child's brain during the second episode of herpes simplex virus (HSV) central nervous system (CNS) disease shows approximately 25 small hyperintense lesions within the corona radiata and peripheral white matter of the frontal and parietal lobes. These lesions are visible on T2-weighted sequences but not on T1-weighted sequences. They do not enhance, and they were not present on the magnetic resonance imaging (MRI) immediately after the neonatal episode of HSV CNS disease. The lesions were believed to be most in keeping with microangiopathic changes. (B) Follow-up MRI (4 months after the MRI in A) shows multiple foci of T2 hyperintensity within the deep and subcortical white matter of the frontal, parietal, and occipital lobes. Most appear unchanged, a few are less conspicuous, and there are no new lesions. The lesions were believed to be nonspecific, but most likely postinflammatory in nature with demyelination or ischemia also in the differential.
recurrences also could follow several years after infantile acyclovir suppressive therapy has stopped. Clinicians should remain diligent in monitoring for this possibility in children who have survived neonatal HSV CNS disease.
